Novavax’s Covid-19 vaccine candidate is currently in a Phase IIb clinical trial. Credit: Jernej Furman. Novavax has selected AGC Biologics,.
As part of the collaboration,the
Novavax announced plans to develop a Covid-19 vaccine candidate in January and begin testing its candidates in animal models in February.
Previously, the company developed MERS and SARS vaccines, said to have shown encouraging immunogenicity and complete protection in preclinical testing.
The company selectedas its lead candidate in May. It secured $4m and up to $384m funding commitment from the Coalition for Epidemic Preparedness Innovations (CEPI) in March and May, respectively.
Last month, Novavax acquired Czech Republic-based Praha Vaccines for approximately $167m to support the manufacture of its Covid-19 vaccine candidate, currently in a Phase IIb clinical trial.